

## Express Mail No. EV 456 919 625 US

WITHE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Falb et al.

Confirmation No.:

2738

Serial No.:

09/970,820

Art Unit:

1636

Filed:

October 5, 2001

Examiner:

MICHAEL D BURKHART

For:

COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF CARDIOVASCULAR Attorney Docket No:

7853-0248-999 (709181-999242)

DISEASE

## AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants have carefully considered the non-final Office Action mailed November 3, 2004, in connection with the above-captioned patent application. Reconsideration of the claims in light of the amendments and remarks that follow is respectfully requested.

This paper includes:

Amendments to the Specification beginning on page 3; Amendments to the Claims beginning on page 4; and Remarks beginning on page 7.

Furthermore, filed herewith in addition to the present amendment and response are:

- 1) a Petition for Extension of Time Under 37 C.F.R. § 1.136(a) extending the period for response by two months from <u>February 2, 2005</u> to and including <u>April 4, 2005</u> (April 3, 2005, falling on a Sunday);
- 2) an Amendment Fee Transmittal Sheet;
- a Revocation and Power of Attorney by co-assignee, Brigham and Women's Hospital;
- 4) a Revocation and Power of Attorney by co-assignee, Millennium Pharmaceuticals, Inc.

- 5) a Change of Address for Registered Patent Attorneys or Agent;
- a Petition to Accept an Unintentionally Delayed Claim for Priority under 37 C.F.R. § 1.78;
- 7) Exhibit A, a copy of page 332-336 of Paul *et al.*, <u>Fundamental Immunology</u>, (Raven Press, New York, 2d ed. 1989);
- 8) Exhibit B, a copy of page 27 of Golub *et al.*, <u>Immunology A Synthesis</u>, (Sinauer Associates Inc., 2d ed. 1991);
- 9) a Statement by Attorney for Applicants Regarding Permanence and Availability of Deposited Microorganism, including Exhibit 1 (viability statement and accompanying cover letter);
- 10) an Information Disclosure Statement; and
- 11) List of References and a copy of accompanying references.